Lucid Diagnostics Inc. (LUCD)
NASDAQ:LUCD
Want to see LUCD full AI Analyst Report?
LUCD Stock Chart & Stats
$1.22
>-$0.01(-1.09%)
At close: 4:00 PM EST
$1.22
>-$0.01(-1.09%)
Day’s Range― - ―
52-Week Range$0.95 - $1.70
Previous CloseN/A
Volume130.18K
Average Volume (3M)608.46K
Market Cap
$249.49M
Enterprise Value-$34.55B
Total Cash (Recent Filing)$34.70B
Total Debt (Recent Filing)$25.82M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
May 18, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding176,945,970
10 Day Avg. Volume663,094
30 Day Avg. Volume608,459
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)10.16
Price to Sales (P/S)23.61
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-138.49
Enterprise Value/Revenue-7.34K
Enterprise Value/Gross Profit13.21K
Enterprise Value/Ebitda614.46
Forecast
1Y Price Target
$4.10Price Target Upside236.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.25
Revenue Forecast (FY)$9.94M
Bulls Say, Bears Say
Bulls Say
Government Contract ExpansionAward of a contract with the Department of Veterans Affairs opens access to a large integrated healthcare system, creating a meaningful new customer channel that can boost testing volumes and revenue.
Medicare Coverage ProspectsA favorable Contractor Advisory Committee outcome increases the likelihood of Medicare issuing a local coverage decision for EsoGuard, which would expand payer access and significantly broaden potential market adoption.
Reimbursement And Payor AccessProgress on private payor billing and use of alternative reimbursement pathways provides expanding routes to insurer payment, supporting broader coverage and wider test adoption.
Bears Say
Liquidity And Fundraising RiskCurrent cash levels combined with ongoing operating losses indicate a likely need to raise additional capital to fund operations and commercialization, which may dilute shareholders or pressure the stock.
Rising Operating ExpensesOperating expenses running above analyst estimates and increasing cash burn pressure available resources and raise the risk of operational constraints if revenue growth does not keep pace.
Lucid Diagnostics News
LUCD FAQ
What was Lucid Diagnostics Inc.’s price range in the past 12 months?
Lucid Diagnostics Inc. lowest stock price was $0.95 and its highest was $1.70 in the past 12 months.
What is Lucid Diagnostics Inc.’s market cap?
Lucid Diagnostics Inc.’s market cap is $249.49M.
When is Lucid Diagnostics Inc.’s upcoming earnings report date?
Lucid Diagnostics Inc.’s upcoming earnings report date is May 18, 2026 which is in 30 days.
How were Lucid Diagnostics Inc.’s earnings last quarter?
Lucid Diagnostics Inc. released its earnings results on Mar 26, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.092 by -$0.008.
Is Lucid Diagnostics Inc. overvalued?
According to Wall Street analysts Lucid Diagnostics Inc.’s price is currently Undervalued.
Does Lucid Diagnostics Inc. pay dividends?
Lucid Diagnostics Inc. does not currently pay dividends.
What is Lucid Diagnostics Inc.’s EPS estimate?
Lucid Diagnostics Inc.’s EPS estimate is -0.06.
How many shares outstanding does Lucid Diagnostics Inc. have?
Lucid Diagnostics Inc. has 176,945,970 shares outstanding.
What happened to Lucid Diagnostics Inc.’s price movement after its last earnings report?
Lucid Diagnostics Inc. reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.092. Following the earnings report the stock price went down -3.361%.
Which hedge fund is a major shareholder of Lucid Diagnostics Inc.?
Currently, no hedge funds are holding shares in LUCD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lucid Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.10 (236.07% Upside)
$4.10 (236.07% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 29.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.67%
12-Months-Change
Fundamentals
Return on Equity
-591.09%
Trailing 12-Months
Asset Growth
31.68%
Trailing 12-Months
Company Description
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
LUCD Company Deck
LUCD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of strong commercial and clinical momentum—notably higher test volumes, a VA FSS contract at Medicare-aligned pricing, a large real-world study with excellent operational metrics, and advancing payer engagements—balanced against meaningful near-term financial and reimbursement risks. The company has demonstrated product/market fit and payer traction, but current revenue recognition limitations, claim adjudication challenges, a high cash burn rate, and dependence on the timing of Medicare’s LCD materially constrain near-term cash flow and ability to scale until coverage is finalized.View all LUCD earnings summariesLUCD Stock 12 Month Forecast
Average Price Target
$4.10
▲(236.07% Upside)
Technical Analysis
Ownership Overview
6.01% Insiders
3.59% Mutual Funds
0.13% Other Institutional Investors
85.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---